{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-297901","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2021-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.569035+00:00","generated_at":"2026-06-28T21:02:19.662988+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Catalyst Biosciences CFO Clinton Musil resigns; controller Seline Miller named interim CFO","bullets":["Clinton Musil resigns as CFO effective Oct 29, 2021 for personal reasons; will provide consulting services.","Seline Miller promoted to SVP Finance and named interim CFO and principal accounting officer.","Miller's base salary increased to $300k (from $250k) and bonus target raised to 30% (from 25%).","Company initiates search for a permanent CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-297901","json":"https://secwatch.observer/filing/0001193125-21-297901.json","markdown":"https://secwatch.observer/filing/0001193125-21-297901.md","text":"https://secwatch.observer/filing/0001193125-21-297901.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/d230267d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T21:02:19.662988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"451c360b87","claim":"Clinton Musil resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"On October 7, 2021, Clinton Musil, Chief Financial Officer of Catalyst Biosciences, Inc. (the “Company”), notified the Company of his decision to resign for personal reasons.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"b0555312cb","claim":"Seline Miller changed role as Senior Vice President, Finance and interim Chief Financial Officer at GYRE THERAPEUTICS, INC..","evidence_excerpt":"Seline Miller, the Company’s Controller, was promoted to Senior Vice President, Finance and will serve as the Company’s interim Chief Financial Officer and interim Principal Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124105/000119312521297901/0001193125-21-297901-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Senior Vice President, Finance and interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}